Providence, RI, United States of America

Anne Searls De Groot

USPTO Granted Patents = 18 (Patent Applications = 25)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 22)

Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 88(Granted Patents)

Company Filing History:

The General Hospital Corporation

patents

1 out of 2

Innatoss Laboratories B.v.

patents

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12016909 - Regulatory T cell epitopes, compositions and uses thereof (2024-06-25),

2. 11911414 - Regulatory T cell epitopes (2024-02-27),

3. 11844826 - Regulatory T cell epitopes, compositions and uses thereof (2023-12-19),

4. 11690902 - epitopes for T cell-targeted Q fever vaccines (2023-07-04),

5. 11045532 - Regulatory T cell epitopes, compositions and uses thereof (2021-06-29),

6. 11045531 - Regulatory T cell epitopes, compositions and uses thereof (2021-06-29),

7. 11045530 - Regulatory T cell epitopes, compositions and uses thereof (2021-06-29),

8. 11045529 - Regulatory T cell epitopes, compositions and uses thereof (2021-06-29),

9. 11045528 - Regulatory T cell epitopes, compositions and uses thereof (2021-06-29),

10. 10980867 - Regulatory T cell epitopes, compositions and uses thereof (2021-04-20),

11. 10925942 - Regulatory T cell epitopes, compositions and uses thereof (2021-02-23),

12. 10925941 - Regulatory T cell epitopes, compositions and uses thereof (2021-02-23),

13. 10925940 - Regulatory T cell epitopes, compositions and uses thereof (2021-02-23),

14. 10925939 - Regulatory T cell epitopes, compositions and uses thereof (2021-02-23),

15. 10751397 - Regulatory T cell epitopes, compositions and uses thereof (2020-08-25),

Title: Anne Searls De Groot: Innovating in Immunology

Introduction: Anne Searls De Groot is a prominent inventor based in Providence, RI, known for her contributions to the field of immunology through her innovative research and development. With 18 patents to her name, she has made significant strides in understanding and utilizing regulatory T cell epitopes, which play a crucial role in immune regulation.

Latest Patents: Among her latest inventions, one notable patent focuses on regulatory T cell epitopes and their various applications. This patent is dedicated to T cell epitopes that comprise a peptide or polypeptide chain, which includes at least a portion of an immunoglobulin's constant or variable region. The patent elaborates on the methods of producing and utilizing these epitopes, showcasing her deep understanding of immunological mechanisms. Another significant patent involves compositions that include regulatory T cell epitopes, where the polypeptides are derived from specific sequences (SEQ NOS: 1-124) with the possibility of incorporating additional amino acids. These innovations underline her expertise in immunopeptide development and their applications in therapeutic settings.

Career Highlights: Anne has built an impressive career with vital contributions to the scientific community. She has worked for various organizations, including Epivax, Inc. and The General Hospital Corporation, where she focused on advancing immunological research and developing new therapeutic solutions. Her extensive portfolio of patents reflects her dedication to innovation and her impact on the industry.

Collaborations: Throughout her career, Anne has collaborated with prominent researchers, such as William Martin and Daniel S. Rivera. These partnerships have been instrumental in pooling knowledge and expertise to push the boundaries of immunological research and application.

Conclusion: Anne Searls De Groot exemplifies the spirit of innovation in the field of immunology. Her extensive patent portfolio and significant collaborations demonstrate her commitment to advancing healthcare through her groundbreaking work on regulatory T cell epitopes. As she continues to innovate, her contributions will undoubtedly influence the future of immunology and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.